9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma

Cancer

Volumn 80, Issue 9, 1997, Pages 1727-1732

  Saltz, Leonard B ^a   Kemeny, Nancy E ^b   Tong, William ^b   Harrison, John ^b   Berkery, Regina ^b   Kelsen, David P ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

9 aminocamptothecin; Colorectal carcinoma; Phase II trial

Indexed keywords

9 AMINOCAMPTOTHECIN; FLUOROURACIL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; AGRANULOCYTOSIS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0030667871     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19971101)80:9<1727::AID-CNCR5>3.0.CO;2-B     Document Type: Article

References (30)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1996; 46:5-27.
2. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321-6.
3. Wolmark N, Rockette H, Fisher B, Wickerman DL, Redmond C, Fisher ER, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol CO-3. J Clin Oncol 1993;11:1879-87.
4. International Multicenter Pooled Analysis of Colon Cancer Trials Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939-44.
5. Blumgart LH, Fong Y. Surgical options in the treatment of hepatic metastasis from colorectal cancer. Curr Prob Surg 1995;32:333-428.
6. Moertel CG. Chemotherapy of colorectal cancer. N Engl J Med 1994;330:436-42.
7. Poon MA, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991;9:1967-72.
8. Buroker TR, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Mailliard JA, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12:14-20.
9. Leischman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995;13:1303-11.
10. Hill M, Norman A, Cunningham D, Findlay M, Nicolson V, Hill A, et al. Royal Marsden Phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol 1995;13:1297-302.
11. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988;48:1722-6.
12. Hsiang YH, Lihou M, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989;49:5077-82.
13. Hertzberg RP, Caranfa MJ, Hecht SM. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 1989; 28:4629-38.
14. Conti JA, Kemeny NE, Saltz LB, Ying H, Tong W, Chou TC, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996;14:709-15.
15. Shimada Y, Yoshino M, Wakui A, Nakao I, Futasuki K, Sakata Y, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993; 11:909-13.
16. Rothenberg ML, Eckert JR, Kuhn JG, Burris HA, Nelson J, Hilsenbeck SG, et al. Phase II trial of Irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996;14:1128-35.
17. Giovanella BC, Stehlin JS, Wall ME. DNA topoisomerase I-targeted chemotherapy of human colon cancer xenografts. Science 1989;246:1046-8.
18. Miller AB, Hoogstrated B, Staquet M. Reporting of cancer treatment. Cancer 1981;47:207-14.
19. Dahut W, Harold N, Takimoto C, Allegra C, Chen A, Hamilton JM, et al. A phase I trial of 9-aminocamptothecin (9-AC) in adults with solid tumors. Proc ASCO 1994;13:138.
20. Supko JG, Malspeis LA. A reversed phase HPLC method for determining camptothecin in plasma with specificity for the intact lactone form of the drug. J Liquid Chromatogr 1991;14:1779-803.
21. Wall ME, Wani MC, Cook CE. Plant antitumor agents: the isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Amer Chem Soc 1966;88:3890-9.
22. Giovanella BC, Hinz HR, Kozielski AJ, Stehlin JS, Silber R. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res 1991;51:3052-5.
23. Rubin E, Wood V, Bharti A, Trites D, Lynch C, Hurwitz, S, et al. A phase I and pharmacologic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res 1995;1:269-76.
24. Takimoto CH, Dahut W, Harold N, Morrison GB, Quinn MF, Cullen E, et al. A phase I trial of a prolonged infusion of 9-aminocamptothecin (9-AC) in adult patients with solid tumors. Proc Am Soc Clin Oncol 1996;15:488.
25. Abigerges D, Armand JP, Charbot GG. High dose intensity of CPT 11 administered as single dose every 3 weeks: the Institute Gustave Roussy experience. Proc Am Soc Clin Oncol 1993;12:133.
26. Rothenberg ML, Kuhn JG, Burris HA III, Nelsom J, Eckardt JR, Tristan-Morales M, et al. Phase I and pharmacologic trial of weekly CPT-11. J Clin Oncol 1993;11:2194-204.
27. Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, et al. A phase I clinical and pharmacologic study of irinotecan HCl (irinotecan, CPT-11), 5-fluorouracil, and leuovorin in patients with advanced solid tumors. J Clin Oncol 1996;14:2959-67.
28. Saltz L, Sirott M, Young C, Tong W, Niedzwiecki D, Yao TJ, et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte-colony stimulating factor. J Natl Cancer Inst 1993;85:1499-507.
29. Rowinsky EK, Grochow LB, Hendricks CB, Ettingen DS, Forastiere AA, Hurowitz LA, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992; 10:647-56.
30. Creemers GJ, Gerrits CHJ, Planting ASTh, Schellens JHM, vd Burg MEL, de Boer-Dennert M, et al. Phase II study of topotecan administered as a 21 days continuous infusion to patients with colorectal cancer. Eur J Cancer 1995;31A, Suppl 5:S146.